Drug reference

Brodalumab

Monoclonal Antibody · Psoriasis Agent

Monoclonal AntibodyPsoriasis Agent

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 12 →

AdalimumabSevereDatabaseDDInter
BaricitinibSevereDatabaseDDInter
CertolizumabSevereDatabaseDDInter
CladribineSevereDatabaseDDInter

Mechanism

Brodalumab is a monoclonal antibody that inhibits the activity of interleukin-17RA. It specifically blocks IL-17 by binding to the IL-17 receptor itself, thereby preventing IL-17 from binding to its receptor.

Indications

Moderate to severe plaque psoriasis in patients who are candidates for systemic therapypatients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

Dosing

Adult: These amounts are usually suitable for an adult for a single daily application for 2 weeks Compound preparations The advantages of including other substances (such as antibacterials or antifungals) with corticosteroids in topical preparations are uncertain, but such combinations may have a place where inﬂammatory skin conditions are associated with bacterial or fungal infection, such as infected e…

Contraindications

Concurrent live vaccines
Active or previous TB infection (patients should be evaluated prior to treatment)

Side effects

Serious

increased risk of serious infections
increased risk of inflammatory bowel disease (ibd), including crohn’s disease and ulcerative colitis
suicidal ideation and behavior